大伸化学 raised its consolidated current-period ordinary profit forecast to ¥2.49 billion through an upward revision, again updating its record-profit outlook. Cumulative second-quarter ordinary profit was ¥1.88 billion, 2.8 times the year-earlier level.
大伸化学 announced its earnings after the close of trading on 12 November. Consolidated ordinary profit for the first half (April–September) of the fiscal year ending March 2027 was ¥1.88 billion, 2.8 times the year-earlier level, exceeding the previous forecast of ¥1.44 billion. At the same time, the full-year ordinary profit forecast was revised upward by 22.7% to ¥2.49 billion from the previous ¥2.03 billion, raising the expected growth rate from 64.2% to 2.0 times.
Based on first-half results and the second-half outlook, consolidated ordinary profit for October–March is forecast at ¥600 million, up 6.2% YoY. Over the latest three months, ordinary profit for July–September was ¥870 million, up 77.4% YoY, while the operating margin on sales improved from 5.6% to 8.2%.